Articles & Insights

Returns, Reconciliation, and Destruction: Mastering the Unglamorous End of the Supply Chain

Nobody joins clinical supply for the returns process. Yet the end of the chain — counting what came back, reconciling it against what was dispensed, and documenting its destruction — is where GCP accountability gets proven, where inspectors reliably look, and where study close-outs quietly stall for months. Drug accountability isn't bureaucratic garnish: it's the evidence that every unit of investigational product is traceable from release to final disposition. Programs that treat it as an end-of-study scramble pay in findings, fees, and timeline. Programs that design it in from day one barely notice it happening.

IRT Supply Settings: The Hidden Levers That Make or Break Trial Supply

Interactive Response Technology (IRT — also called RTSM) is the system that randomizes patients and manages drug supply across a trial: assigning kits, tracking inventory, and triggering shipments to sites. Most sponsors treat IRT configuration as a systems task delegated to the vendor. That's a mistake. Buried in the IRT's supply settings are a handful of parameters — buffer levels, resupply triggers, prediction windows, pooling rules — that quietly determine whether a trial ships tons of overage it will destroy, or gambles with stock-outs that pause dosing. IRT setup is supply strategy, expressed in configuration.

Clinical Trial Supply Costs: Where the Money Actually Goes (and How to Stop the Leaks)

Ask a study team where the supply budget goes and you'll hear about drug manufacturing and shipping. Ask the invoices, and a different story emerges: the big money moves through overage that gets destroyed, comparator purchases nobody scrutinized, expedited shipments covering planning gaps, and end-of-study returns and destruction that everyone forgot to budget. Clinical supply is one of the least examined major line items in development — which is precisely why it's one of the most compressible. Here's where the money actually goes, and which levers genuinely move it.

Protocol Amendments and Clinical Supply: Designing for the Change You Know Is Coming

Most clinical trials are amended - typically more than once - and modern adaptive and platform designs make mid-course change a feature, not an accident. Yet clinical supply chains are still routinely designed as if the original protocol were permanent: labels printed for one visit schedule, kits built for one dose, IRT configured for one arm structure. When the amendment lands, the supply chain discovers its rigidity the expensive way - relabeling campaigns, destroyed stock, dosing delays. The fix isn't predicting every change. It's designing supply for changeability from day one.

Temperature Excursions in Clinical Supply: A Practical Response Playbook

A temperature excursion is any departure from a product's labeled storage conditions — the moment a 2–8°C shipment logs 10.4°C for ninety minutes on an airport tarmac. Excursions are not rare events to be embarrassed about; they are a statistical certainty of global distribution. What separates well-run supply chains from chaotic ones is not zero excursions — it's a fast, pre-built response process that protects patients, preserves product, and keeps sites dosing.

Direct-to-Patient Clinical Supply: When DtP Models Make Sense (and When They Don't)

Direct-to-patient (DtP) supply means shipping investigational product from a depot, pharmacy, or site directly to the patient's home rather than requiring every dose to be dispensed in person at the clinical site. Done well, DtP widens recruitment, protects retention, and makes decentralized trial designs viable. Done casually, it multiplies your temperature excursions, complicates accountability, and creates regulatory exposure across every jurisdiction you ship into. The difference is design.

5 Metrics Every Clinical Supply Leader Should Report to the Board

Most clinical supply reporting fails upward. The metrics that a supply team lives by — resupply triggers, shipment counts, depot inventory levels — are operationally vital and almost entirely meaningless to a board. Present them to executives and you get polite nods and no engagement, right up until something goes wrong and the board suddenly wants to know why they never saw it coming.

Inspection Readiness: How to Make Your Clinical Supply Chain Audit-Proof

There are two kinds of clinical supply operations: the ones that prepare for an inspection when one is announced, and the ones that are simply ready, all the time, because readiness is how they run day to day. The first kind spends the weeks before an inspection in a frantic scramble to reconstruct records and close gaps. The second kind barely changes its behavior, because there's nothing to reconstruct.

Direct-to-Patient Trials: Supply Chain Considerations for Decentralized and Hybrid Studies

For decades the clinical supply chain had a comfortable stopping point: the site. Drug moved from manufacturing, through depots, to the investigator site, and the site handled the last, most sensitive step — dispensing to the patient. Decentralized and direct-to-patient trials erase that stopping point. Now the supply chain runs all the way to the patient's front door.

Pharma Supply Chain Risk Management: A Framework for the Top 10 Risks (and How to Mitigate Each)

Ask ten supply chain leaders what their biggest risk is and you'll get ten different answers — which is exactly the problem. Risk in a pharmaceutical supply chain isn't one thing. It's a portfolio of distinct threats, each with its own causes, its own warning signs, and its own mitigations. Treating them as a vague single worry ("what if supply fails?") is how they stay unmanaged.

Build vs Buy: When to Hire a Clinical Supply Consultant vs Build the Function In-House

Every growing biotech reaches the same fork in the road. The clinical supply chain has become too complex and too consequential to keep handling off the side of someone's desk — and now there's a decision to make. Do you hire and build an internal supply function, or bring in a consultant or partner who already has the expertise?

Cell and Gene Therapy Supply Chains: Why Autologous Logistics Break the Traditional Model

Every assumption a conventional pharmaceutical supply chain is built on quietly disappears the moment you're handling an autologous cell therapy.

Packaging and Labeling Strategy for Global Trials: Booklet Labels, Pooling, and Expiry Management

Packaging and labeling is where a global trial's flexibility is either created or destroyed — and the decision is made months before anyone notices which one happened.

Import, Export, and Customs for Clinical Supplies: Avoiding the Delays No One Plans For

Every element of a global trial's supply chain gets a plan — the forecast, the packaging strategy, the depot network, the resupply logic. And then the drug reaches a border, and all of that careful planning waits in a customs queue behind a paperwork error nobody budgeted time for.

GMP vs GDP: The Compliance Distinction That Defines Your Supply Chain

Two acronyms, one letter apart, and an enormous amount of confusion between them. GMP and GDP get used almost interchangeably in casual conversation — and then someone in an audit asks precisely which one governs a particular activity, and the room goes quiet.

Reshoring and Tariffs: What Domestic Manufacturing Really Means for Your Supply Strategy

For a generation, pharmaceutical supply chains were built around a simple logic: source the active ingredient wherever it was cheapest, manufacture wherever it was most efficient, and move the product across borders that barely registered as a cost. In 2026, that logic is being rewritten in real time — and every supply chain leader now has to decide how to respond.

Demand Forecasting for Adaptive and Basket Trial Designs

A conventional trial gives your supply chain something precious: a plan that doesn't change. Fixed arms, fixed allocation, a known set of countries. Uncertain, yes — enrollment is always uncertain — but structurally stable. You're forecasting one trial.

The Hidden Cost of "Just-in-Case" Inventory in Clinical Trials

Nobody ever got called into a meeting to explain why there was too much drug.

Expiry Management and Stability Budgeting: Extending Drug Supply Without Adding Risk

Every kit in your trial is running two clocks at once. One counts down enrollment and dispensing — the demand you're trying to meet. The other counts down shelf life — the window in which the drug is usable at all. Manage the first well and mismanage the second, and you can still end up destroying perfectly forecast supply simply because it aged out before a patient could use it.

IRT/RTSM UAT: A Sponsor's Guide to Testing Your Randomization System Before Go-Live

Your IRT system will randomize patients, assign kits, protect the blind, and trigger every resupply shipment for the life of the trial. It is, functionally, the brain of your clinical supply chain.

DSCSA in 2026: What's Now Enforced and What the Final Deadline Means for Your Supply Chain

If you're a sponsor moving toward commercial launch, or you're operating anywhere in the US prescription drug distribution chain, here's what actually applies now and what the last deadline means.

Vendor and Depot Management: The Sponsor's Checklist for Global Clinical Trials

In a global trial, you don't run your own supply chain. You run a network of other people's — a CMO here, a packaging vendor there, a central depot, three regional depots, a courier network, and sixty sites. Your drug spends almost its entire life in someone else's building or someone else's truck.

Comparator Sourcing: How to De-Risk Your Comparative Drug Supply Strategy

Roughly two-thirds of clinical trials rely on a comparator or co-therapy — and sourcing it is one of the most underestimated parts of the whole supply chain. In one industry survey, around three-quarters of respondents said they'd hit a challenge sourcing comparators or ancillaries. And the money is far from trivial: by some long-standing estimates, sponsors spend on the order of $50 million on clinical supplies for a program, with roughly half of that going to comparators.

Why Most Clinical Supply Risk Registers Fail — and What to Track Instead

If you've spent any time in clinical supply, you know the artifact: a spreadsheet with forty rows, each scored on a probability-times-impact scale, color-coded red-amber-green, built during study start-up, presented once at a kickoff meeting, and then quietly abandoned.

Cold Chain Excursions: Building a CAPA Process That Keeps Biologics Trials Inspection-Ready

The biopharma industry loses an estimated $35 billion a year to failures in temperature-controlled logistics — lost product, replacement costs, wasted shipping, and the root-cause work that follows. For a clinical trial, the math is even more painful, because the product that just sat on a hot tarmac for six hours isn't a commercial SKU you can remanufacture next week. It's irreplaceable investigational material tied to a specific patient on a specific visit date.

AI in Clinical Supply Chain: Where It Actually Helps (and Where It's Hype)

Clinical Supply Forecasting: How to Prevent Stockouts and Overage Across Multi-Site Trials

There are two ways a clinical supply chain can embarrass you. The first is a stockout — a patient arrives for a visit and the drug isn't there. The second is the quieter, more expensive one: at the end of the trial you destroy a warehouse full of unused, expired product. Both come from the same root cause. Both are forecasting failures.

What Is Clinical Trial Supply Chain Management? A Sponsor's Complete Guide

A clinical trial can take 10 to 15 years and frequently costs well over a billion dollars to bring a single drug to market — and only about one in eight molecules that enter clinical testing ever reaches approval.

Cold Chain 2.0: Building a Resilient Temperature Controlled Network for Biologics and Gene Therapies

Cold chain failures don’t just cost money — they destroy product, delay treatment, and erode trust. Biologics and cell/gene therapies demand a level of temperature control that legacy cold chain systems were never designed to handle. The next generation of cold chain — Cold Chain 2.0 — integrates real‑time monitoring, redundancy, predictive analytics, and digital […]

The ROI of Better Decision Hygiene: How Structured Thinking Saves Millions

What if the biggest cost driver in your clinical supply chain isn’t API, packaging, or logistics—but the quality of your decisions? In clinical supply, we obsess over precision: forecasts, expiry dating, depot capacity, comparator sourcing, packaging runs, IVR thresholds. Yet the real leverage point is often upstream—how teams think, structure information, and make decisions under […]

What Great Clinical Supply Leaders do Differently : A pattern I’ ve seen across companies.

What if the biggest difference between average clinical supply leaders and great ones isn’t resources, headcount, or technology — but the patterns in how they think and operate? Across companies, therapeutic areas, and organizational maturities, I keep seeing the same behaviors separate the truly exceptional from the merely functional. Three patterns stand out: 1. They […]

The Three Types of Supply Chain Fire Drills — and How to Eliminate Each One

What if the “urgent” issues consuming your team aren’t actually emergencies—just symptoms of a system you haven’t redesigned yet?     In clinical supply chain, fire drills don’t just burn time. They burn credibility, budget, and study timelines. After 25+ years in this space, I see the same three patterns repeat across sponsors, CROs, and […]

The Rise of Domestic Manufacturing: What It Means for Commercial Supply Chain Strategy

Strategy Reshoring isn’t a trend — it’s a structural shift that will redefine pharma operations for the next decade. Tariffs, geopolitical instability, and FDA policy shifts are accelerating the move toward domestic manufacturing. But the impact goes far beyond facility location. It reshapes sourcing strategies, capacity planning, cost structures, and risk models across the entire […]

The 5 Questions Every Supply Chain Leader Should Ask Weekly: A Leadership Cadence That Prevents Surprises

When was the last time your supply chain told you something you didn’t already know?   After almost three decades leading global operations and clinical supply teams, I’ve learned this: Surprises rarely come from complexity — they come from leaders not asking the right questions often enough.   A disciplined weekly cadence is one of […]

What I’ve learned leading Global Ops across 25 years: A leadership reflection with a sharp takeaway

What if the greatest test of leadership isn’t how well you perform in moments of clarity—but how you show up when the path forward is anything but clear? After 25 years leading global operations across the pharmaceutical value chain, that question has shaped more of my career than any KPI, system upgrade, or organizational redesign. […]

The Hidden Cost Drivers in Clinical Packaging and Labeling: Most Sponsors think packaging is a commodity; their invoices tell a different story

What if the biggest financial leak in your clinical trial isn’t your drug, your depot, or your comparator—but the packaging decisions your team made long before the first patient was enrolled? Clinical packaging and labeling quietly consume more budget than most teams realize. The real cost drivers aren’t materials—they’re changeovers, artwork cycles, batch sizes, and […]

The Myth of the Perfect Forecast: Why Probabilistic Thinking Beats Precision

What if your next “perfect forecast” is actually your biggest blind spot? After more than two decades in pharmaceutical supply chains, I’ve seen one thing over and over — our collective obsession with precision. We chase the perfect model, the richest dataset, the ultimate algorithm… all hoping we’ll finally predict the future. But the truth? […]

The Hidden Power of Packaging Strategy: How Packaging Decisions Quietly Drive Timelines and Costs

What if the biggest risk to your First-Patient-In (FPI) date isn’t the recruitment site, but the kit design? In my 25+ years in pharmaceutical supply chain, I’ve watched many Clinical Trial Managers (CTMs) navigate the grueling path of protocol design and site selection, only to be blindsided by “the box.” While your focus is rightfully […]

Why AI Won’t Save a Broken Process: tech is not a substitute for operational discipline

If your clinical supply process is inconsistent, undocumented, or dependent on heroics, what exactly do you expect AI to optimize? There’s a growing belief that layering AI on top of operational chaos will magically create efficiency. But in clinical supply, where patient safety, expiry management, and global coordination hinge on precision, AI doesn’t fix […]

The most overlooked Risk in Clinical Supply: a provocative take on data integrity and handoffs

What if the biggest risk in your clinical supply chain isn’t forecasting, recruitment volatility, or vendor performance — but the silent erosion of data integrity every time information changes hands? We talk endlessly about systems, platforms, and digital transformation. Yet the real cracks often appear in the mundane moments: a spreadsheet emailed instead of uploaded, […]

Leadership and Excellence in the Modern Clinical Supply Chain

The clinical supply chain has evolved from an operational function into a strategic enabler of trial readiness, regulatory success, and patient impact. As therapies advance and global trials expand, leadership—not management—defines the difference between execution and sustained excellence. This article highlights the leadership capabilities that elevate performance across communication, team development, change management, executive reporting, […]

Why Managing Clinical Supply Chain Costs Will Define 2026

December 30, 2025 Clinical supply chain leaders are entering 2026 with a new mandate: control costs without compromising flexibility, quality, or patient access. The pressure is real—and the organizations that get this right will accelerate development while everyone else fights fires. Here’s what’s driving the urgency: 🔹 Rising manufacturing & packaging costs Energy, […]

Clinical Supply Chains Are Entering Their “AI‑Native” Era — And 2026 Is the Breakout Year

Clinical Supply Chains Are Entering Their “AI‑Native” Era — And 2026 Is the Breakout Year For decades, clinical supply has been treated as a back‑office function. In 2026, it’s becoming a strategic engine — one that accelerates development timelines, reduces cost, and expands global patient access. The catalyst? AI is no longer an experiment. It’s the new […]

The Changing Landscape of Clinical Trial Supply Chains- Emergence of AI

https://www.linkedin.com/in/jgoberlander/?lipi=urn%3Ali%3Apage%3Ad_flagship3_pulse_read%3B6xTGMp88S8yrUkVanKmQOw%3D%3D Joseph G. Oberlander, Ph.D., PMP Program Manager ♦ Neuroscientist ♦ Author Clinical trials are the backbone of medical innovation, but their supply chains have traditionally been complex, fragmented, and vulnerable to disruption. From ensuring investigational drugs reach patients on time to managing global logistics, the stakes are high. Artificial Intelligence (AI) is now emerging […]

Clinical Supply Chain Outlook Heading Into 2026

As 2025 closes, several December analyses across healthcare and supply chain publications point to the same conclusion: clinical supply chains are entering 2026 with higher volatility, tighter capacity, and increasing regulatory scrutiny — but also unprecedented opportunities for digital acceleration. A few patterns stand out: 1. Non‑labor cost pressure is now a structural reality, not […]